TechBio company NunaBio raises £1.9M in seed funding

NunaBio, a TechBio company producing synthetic DNA for biochemical research, today announced it has raised £1.9m in a seed round with participation from the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures, Pioneer Group, Ascension Life Fund and Martlet Capital.

Founded in April 2021 as a spin-out from Newcastle University, NunaBio is developing a novel method
of DNA synthesis which enables the cost-effective production of oligonucleotides at impressive scale,
speed, and accuracy. The platform will enable synthesis of whole genes and DNA fragments of
unprecedented length without the use of plasmids or primers, which are existing bottlenecks in the
synthetic biology industry.

NunaBio’s technology has broad applications across multiple areas of life sciences, including gene
therapy, T cell engineering, viral vector synthesis, diagnostics, hybridisation capture and targeted
biomarker panels.

Proceeds will be used to expand the Company’s infrastructure to scale-up its existing offering, and to
accelerate research and development. As part of the investment, NunaBio will also join Pioneer
Group’s Launch Venture Building programme, where it will receive wrap-around support from leaders
in the field for starting up, scaling and raising investment. The Company will benefit from
commercialisation support for 12 months.

Joe Hedley, Co-founder and CEO of NunaBio, said: “I am delighted to have the support of top life
sciences investors which will enable us to further evolve our DNA synthesis technology, making our
system one of the most innovative technologies in the market. Our investors share our mission of
delivering accurate, efficient DNA synthesis to have a lasting impact on the world and so we are
delighted they have chosen to invest in NunaBio. We are also excited to be joining Pioneer Group’s
venture building programme and to work closely with its highly experienced life sciences team.”

Glenn Crocker, Head of Ventures at Pioneer Group, said: “NunaBio is pioneering a new era of DNA
synthesis that has the potential to revolutionise the synthetic biology industry and fill a gap across key
life sciences markets. We are impressed by the technology Joe and his team have developed so rapidly
and are proud to be part of this financing round. We also welcome them to our life sciences ecosystem
and look forward to helping them thrive in every step of their innovation journey.”

Alisa Molotova, Investment Manager at Martlet Capital, said: “We are thrilled to support NunaBio’s
novel and disruptive DNA synthesis technology and the talented team behind it. With a dedicated
team pushing the boundaries of what’s possible in DNA synthesis, we can help unlock the potential of
synthetic biology and drive innovation across a wide range of industries. We are excited to be part of
something truly transformative.”

Chris Wheatcroft, Investment Partner at the Ascension Life Fund, said: “We were immediately
impressed with Joe and the NunaBio team and had strong conviction from the outset. We believe
that NunaBio’s technology has the potential to disrupt the synthetic DNA market. They have the right
team and investors to take advantage of a large and growing market opportunity.”

Alex Buchan, Investment Director at Northstar Ventures, said: “We are pleased to support NunaBio,
a spin out from Newcastle University, which is developing cutting edge DNA synthesis technology.
We have been impressed by the company’s recent progress. We strongly believe NunaBio has the
potential to become a major provider of DNA at scale and form an integral part of the rapidly
growing SynBio cluster in the North East.”

Find out more about the North East Innovation Fund